Keep up to date on the latest medical news at MDLinx - FREE!

  • Stay current on the latest medical literature, research and clinical news
  • MD jobs and physician job search at our new medical job Career Center
  • Receive invitations to paid market research
  • Search Clinical Trials and Medical Conferences

register to view free medical at articles at MDLinx

Follow Us

Posts by category

MDLinx Blog - Medical News and more.

Current Articles | RSS Feed RSS Feed

What are Rheumatologists Really Doing Online


What are Rheumatologists Really Doing Online? We know, and we want to tell you.

Did you know that M3 MDLinx is the leading digital provider of clinical news and information to over 85% of all US Rheumatologists?.

Did you know that M3 MDLinx is the leading digital provider of clinical news and information to over 85% of all US Rheumatologists?

Did you know that majority of Rheumatologists actually spend more time online engaged in activities that support care for their patients than on seeking information about new medical advances in their field? Did you think the two were the same? According to Rheumatologists, they aren't.

spending their time on and offline, and what matters most to them. We surveyed over 100 Rheumatologists in the United States, who see at least 200 patients per month, and discovered not just how doctors are communicating with pharma companies, their peers and their patients, but much more. We asked them:

  • How do you want pharma and biotech companies to communicate with you in comparison to how they communicate with you today?
  • Do your pharma and biotech reps provide you with the tools and knowledge you need to best do your job? What can they do better?
  • How often and through what outlets do you interact online for research, news, social, and informational purposes?
  • How often, in what forms and for what reason do you use technology most? How can pharma brands better utilize technology?
  • If you want a basic study with stock answers that vary slightly from year to year, you shouldn't call us. But if you want the inside scoop on what Rheumatologists really want and need, and insight on how they get information and how they share it, you should contact us today.

To learn more about the details of The CompleteRheumatologist Study or purchase the report, contact MDLinx to learn more.



Serum B-cell activating factor assessment in a population of Egyptian patients with systemic sclerosis

International Journal of Rheumatic Diseases, 12/19/2012

Abdo MS et al. – To assess serum B–cell activating factor (BAFF) levels in patients with systemic sclerosis and to correlate this with disease features and disease severity. Serum BAFF levels were significantly elevated in patients with systemic sclerosis irrespective of disease subtype, disease duration or age of patients. This elevation in serum BAFF significantly related to gastrointestinal track involvement and methotrexate therapy.


    • This is a case-control study in which patients with the established diagnosis of SSc were recruited.
    • The diagnosis of SSc was established according to the American Rheumatology Association 1980 criteria for the classification of scleroderma.
    • Patients' assessment included evaluation of skin involvement using the Modified Rodnan score and disease severity using the Medsger score.
    • Twenty-five healthy matching controls were included.
    • The sandwich enzyme-linked immunosorbent assay technique was used for direct assessment of serum BAFF in patients and controls


    • The study included 60 patients (54 female and 6 male), with a mean age of 38.18±12.06 years, with mean disease duration of 7.85±4.075 years.
    • Serum BAFF in patients ranged 98.2-5015 pg/mL with mean BAFF 1100±835.4 pg/mL.
    • In controls serum BAFF levels ranged 188.5-2314 pg/mL with mean BAFF 546.1±471.1 pg/mL, showing a statistically significant elevation of serum BAFF levels in SSc patients (P=0.0001) with insignificant correlation to skin disease or total Medsgar Score of the study population (P>0.05).
    • Serum BAFF levels showed significant correlation with episodes of pseudo-obstruction and methotrexate (MTX) use in the patients studied (P<0.05)

Dr Reem Hamdy A. Mohammed (12/18/2012) comments:

It is really great and we as authors are proud of having our article selected in this great scientific citation, Mdlinx team have been also active, nonreluctant and enthausiastic in encouraging spread of scientific knowledge and anchorage of research knowledge allover

More articles in rheumatology at

Bisphosphates decrease risk of stroke

In a study involving 2148 patients on bisphosphonate therapy and 6444 matched patients with osteoporotic fractures who were followed for 2 years, the risk of stroke was significantly reduced in the former group (8.6% vs. 10.8% [HR=.79]).  Bisphosphonate users had a 0.53- and 0.81-fold risk of subarachnoid and ischemic strokes, respectively, compared to non-users.
All Posts

Trending Medical Articles

Monday, Mar 31, 2014
Journal of Oral Implantology, 03/31/2014 Nayak AG, et al. – Gaps and hollow spaces at the implant abutment interface will act as a bacterial reservoir that may cause peri–implantitis. Hence, the sealing ability of O–ring (in addition to polysiloxane) and GapSeal (an antibacterial sealing gel) was evaluated. The data thus obtained were subjected to statistical analysis by...Read More
Tuesday, Apr 8, 2014
Annals of Rheumatic Diseases, 04/08/2014 Saevarsdottir S, et al. – To study clinical predictors for radiographic progression after 1 year in an early rheumatoid arthritis (RA) trial. In addition to previously described predictors, the authors identified smoking as a strong independent risk factor for radiographic progression in early RA. Methods In the SWEFOT trial population, disease...Read More
Monday, Apr 7, 2014
Physiotherapy, 04/07/2014 Spencer LM, et al. – The aim of this study is to determine if there was an increase in walk distance when two incremental shuttle walk tests (ISWTs) were performed at the commencement of a maintenance exercise program and at three, six and 12–month assessments. The increase in walk distance when a second ISWT was performed at zero and three months...Read More
Tuesday, Apr 15, 2014
Breast Cancer Research and Treatment, 04/15/2014 Guha P, et al. – The authors show that nicotine induces the expression of galectin–3 (an anti–apoptotic β–galactoside–binding lectin) in breast cancer cell line and in primary tumors from breast cancer patients. Galectin–3 or its upstream signaling molecule STAT3 or α9nAChR could be a potential...Read More